Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex Biotechnology has commenced dosing of patients in a Phase III clinical trial of the company's flagship product, Generex Oral-lyn, an oral insulin spray.
Subscribe to our email newsletter
The six-month Phase III study will involve up to 750 patients with Type-1 diabetes mellitus in 36 centers located in the US, Canada, Russia and eastern Europe.
The objective of the study is to compare the efficacy of Generex Oral-lyn and the company’s RapidMist diabetes management system with prandial injections of regular human insulin as measured by HbA1c.
Generex Oral-lyn, a liquid formulation of human regular insulin, is sprayed into the mouth with a simple device similar to inhalers used for the treatment of asthma.
Philip Raskin, managing director of the University of Texas Southwestern Medical Center at Dallas, said: “Diabetes mellitus is an overwhelming worldwide problem. Many people do not achieve their treatment goals because of failure to use insulin. As a principal investigator, I am pleased to announce that the international Phase III non-inferiority study of 750 patients has dosed its first patient.”